7,365 Results

Rolling submission to FDA started for CAM 2038 (buprenorphine depots) in Opioid Use Disorder- Braeburn Pharmaceuticals and Camurus

 Added 21 hours ago

Braeburn Pharmaceuticals and Camurus announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S....

Study suggests Reminyl XL/Razadyne (galantamine hydrobromide) provides benefits in metabolic syndrome- Janssen Pharma

 Added 21 hours ago

Alzheimer's medication Reminyl XL/Razadyne (galantamine hydrobromide) from Janssen Pharma, appears to slash inflammation and insulin resistance in patients with metabolic...

EU Commission approves Kyntheum (brodalumab) of moderate-to-severe plaque psoriasis.- Leo Pharma

 Added 21 hours ago

AstraZeneca and MedImmune, announced that its partner Leo Pharma has been granted full marketing authorisation in all 28 EU member...

EU Commission approves Reagila (cariprazine), for the treatment of schizophrenia .-Recordati + Gedeon Richter.

 Added 1 day ago

Recordati announces that Gedeon Richter Plc. was granted marketing authorization from the European Commission for Reagila (cariprazine), a novel antipsychotic...

Alzheon, Inc makes presentation of data from three studies of ALZ 801, a proposed treatment for Alzheimers Disease at the AAIC meeting.

 Added 1 day ago

Alzheon, Inc.,announced data from the company’s three presentations at the Alzheimer’s Association International Conference (AAIC) held in London on July...

Complete Response Letter from FDA for Evenity (romosozumab) as a treatment for postmenopausal women with osteoporosis. - Amgen +UCB.

 Added 2 days ago

Amgen and UCB announced that the FDA has issued a Complete Response Letter for the Biologics License Application (BLA) for...

FDA maintains clinical hold on Proellex (telapristone acetate), a treatment for uterine fibroids.- Repros Therapeutics

 Added 2 days ago

Repros Therapeutics Inc has announced that it received preliminary feedback from the FDA on the Company's clinical development program for...

Spark Therapeutics announced The Lancet, has published Phase III clinical trial data of voretigene neparvovec, for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease.

 Added 2 days ago

Spark Therapeutics announced The Lancet, has published Phase III clinical trial data of voretigene neparvovec, an investigational, potential one-time gene...

FDA approves Nerlynx (neratinib) to treat patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy.- Puma Biotechnology

 Added 2 days ago

Puma Biotechnology announced that the FDA has approved Nerlynx (neratinib), formerly known as PB272, a once-daily oral tyrosine kinase inhibitor...

Load more